{"id":"NCT00083551","sponsor":"University of Arkansas","briefTitle":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","officialTitle":"UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1998-08","primaryCompletion":"2014-08","completion":"2014-08","firstPosted":"2004-05-27","resultsPosted":"2015-09-22","lastUpdate":"2015-11-23"},"enrollment":668,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Thalidomide","otherNames":["Thalomid"]},{"type":"DRUG","name":"Ara-C","otherNames":["Cytarabine"]},{"type":"DRUG","name":"BCNU","otherNames":["Carmustine"]},{"type":"DRUG","name":"Cisplatin","otherNames":["cisplatinum","cis-diamminedichloroplatinum","Platinol","Platinol-AQ"]},{"type":"DRUG","name":"Cytoxan","otherNames":["Cyclophosphamide","Endoxan","Neosar","Procytox","Revimmune","cytophosphane"]},{"type":"DRUG","name":"Dexamethasone","otherNames":["Tobradex"]},{"type":"DRUG","name":"Doxorubicin","otherNames":["Adriamycin","hydroxydaunorubicin"]},{"type":"DRUG","name":"Etoposide","otherNames":["Eposin","Etopophos","Vepesid","VP-16"]},{"type":"DRUG","name":"Filgrastim","otherNames":["Neupogen","Grafeel","Religrast","Nugraf","Shilgrast","Neukine","Emgrast"]},{"type":"DRUG","name":"Recombinant GM-CSF","otherNames":[]},{"type":"DRUG","name":"Interferon-alpha-2b","otherNames":[]},{"type":"DRUG","name":"Melphalan","otherNames":["Alkeran"]},{"type":"DRUG","name":"Vincristine","otherNames":["Oncovin","leurocristine"]}],"arms":[{"label":"Thalidomide","type":"ACTIVE_COMPARATOR"},{"label":"No Thalidomide","type":"ACTIVE_COMPARATOR"}],"summary":"This study has been designed to evaluate whether \"anti-angiogenesis\" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"6 Years","effectByArm":[{"arm":"Thalidomide","deltaMin":65,"sd":null},{"arm":"No Thalidomide","deltaMin":58,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["16525139","40471585","27581518","22689675"],"seeAlso":["http://myeloma.uams.edu"]},"adverseEventsSummary":{"seriousAny":{"events":323,"n":323},"commonTop":["Grade 1 Bicarbonate decrease","Grade 1 Hypokalemia","Grade 3 Anemia (HGB)","Grade 2 Hypoalbuminemia","Grade 1 Hyponatremia"]}}